Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Lenacapavir could revolutionize HIV prevention because it is more effective and practical than oral PrEP, and is thus a better fit for those worried about the visibility — and potential stigma ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...